Biotech stocks still have room to rise after the election of Donald Trump as U.S. president, which removed threats of drug price controls that had pushed shares to historically cheap levels this year, a top portfolio manager for Janus said on Wednesday.
The Nasdaq Biotechnology index .NBI has climbed 11 percent since the election, but still remains down 14 percent for 2016.
Given the deregulation of healthcare signaled by Donald Trump, who was elected last week in a surprise victory, that is not enough, according to Janus Global Life Sciences co-portfolio manager Ethan Lovell.
